Where Will TJX Companies Stock Be in 10 Years?
Off-price retail is as popular as ever thanks to social…
Sell
28
GBIO Quote, Financials, Valuation and Earnings
Last price:
$0.95
Seasonality move
:
26.75%
Day range:
$0.94 - $1.02
52-week range:
$0.75 - $4.65
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.39x
P/B ratio:
0.61x
Volume:
932.7K
Avg. volume:
599.5K
1-year change:
-47.04%
Market cap:
$63.3M
Revenue:
$5.9M
EPS (TTM):
-$2.19
Analysts' Opinion
-
Consensus RatingGeneration Bio has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 3 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.00, Generation Bio has an estimated upside of 638.4% from its current price of $0.95.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $0.95.
Fair Value
-
According to the consensus of 6 analysts, Generation Bio has 638.4% upside to fair value with a price target of $7.00 per share.
GBIO vs. S&P 500
-
Over the past 5 trading days, Generation Bio has underperformed the S&P 500 by -0.47% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Generation Bio does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Generation Bio has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Generation Bio reported revenues of $7.6M.
Earnings Growth
-
Generation Bio has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Generation Bio reported earnings per share of -$0.23.
Enterprise value:
-121.5M
EV / Invested capital:
--
Price / LTM sales:
3.39x
EV / EBIT:
--
EV / Revenue:
-6.54x
PEG ratio (5yr expected):
--
EV / Free cash flow:
1.16x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-46.74%
Net Income Margin (TTM):
-782.87%
Return On Equity:
-92.44%
Return On Invested Capital:
-92.44%
Operating Margin:
-221.27%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $18.6M | $2.1M | $7.6M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$137.4M | -$134.8M | -$97.7M | -$31.4M | -$16.7M | |
| EBITDA | -$132.5M | -$129.5M | -$92.6M | -$30.1M | -$15.5M | |
| Diluted EPS | -$2.34 | -$1.98 | -$2.19 | -$0.43 | -$0.23 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $285.8M | $403.3M | $310.6M | $297.8M | $191.3M | |
| Total Assets | $310.9M | $464M | $402.8M | $381.5M | $248.8M | |
| Current Liabilities | $9.2M | $14.5M | $17.3M | $32.8M | $30.2M | |
| Total Liabilities | $24.4M | $56.8M | $94.1M | $149.6M | $144.3M | |
| Total Equity | $286.5M | $407.2M | $308.7M | $231.9M | $104.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$100.2M | -$50.8M | -$97.8M | -$24.9M | -$19.5M | |
| Cash From Investing | -$167M | -$26.2M | $22.3M | -$26.6M | $12.7M | |
| Cash From Financing | $13.3M | $35.8M | $183K | -$131K | -$3K | |
| Free Cash Flow | -$111.2M | -$54.3M | -$104.4M | -$25.5M | -$19.6M | |
GBIO
Sector
Market Cap
$63.3M
$44.9M
Price % of 52-Week High
20.39%
46.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
-47.04%
-33.54%
Beta (5-Year)
--
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$0.93
200-day SMA
Sell
Level
$2.46
Bollinger Bands (100)
Sell
Level
1.26 - 2.52
Chaikin Money Flow
Sell
Level
-7.8M
20-day SMA
Sell
Level
$1.03
Relative Strength Index (RSI14)
Sell
Level
35.93
ADX Line
Sell
Level
23.93
Williams %R
Neutral
Level
-74.891
50-day SMA
Sell
Level
$1.34
MACD (12, 26)
Sell
Level
-0.12
25-day Aroon Oscillator
Sell
Level
-12
On Balance Volume
Neutral
Level
20.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.2119)
Sell
CA Score
(Annual)
Level (-1.4501)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (2.0765)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Stock Forecast FAQ
In the current month, GBIO has received 3 Buy ratings 3 Hold ratings, and 0 Sell ratings. The GBIO average analyst price target in the past 3 months is $7.00.
-
Where Will Generation Bio Stock Be In 1 Year?
According to analysts, the consensus estimate is that Generation Bio share price will rise to $7.00 per share over the next 12 months.
-
What Do Analysts Say About Generation Bio?
Analysts are divided on their view about Generation Bio share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Generation Bio is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is Generation Bio's Price Target?
The price target for Generation Bio over the next 1-year time period is forecast to be $7.00 according to 6 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is GBIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Generation Bio is a Leans Bullish. 3 of 6 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of GBIO?
You can purchase shares of Generation Bio via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Generation Bio shares.
-
What Is The Generation Bio Share Price Today?
Generation Bio was last trading at $0.95 per share. This represents the most recent stock quote for Generation Bio. Yesterday, Generation Bio closed at $0.95 per share.
-
How To Buy Generation Bio Stock Online?
In order to purchase Generation Bio stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will CVS Health Stock Recover?
It’s been a treacherous journey for CVS Health Corporation (NYSE:CVS)…
Why Is AT&T Stock Dropping?
The telecommunications giant AT&T Inc. (NYSE:T) has perhaps surprisingly eclipsed…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 38x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
45
QMCO alert for Jan 16
Quantum [QMCO] is down 0% over the past day.
Buy
51
QRVO alert for Jan 16
Qorvo [QRVO] is down 0% over the past day.
Sell
31
ATEX alert for Jan 16
Anterix [ATEX] is down 0% over the past day.
